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All-trans retinoic acid (ATRA), a carboxylic acid form of
vitamin A, was a revolutionary discovery in the treatment of
acute promyelocytic leukemia (APL) that was found largely
by chance in late 80s. The molecular hallmark of APL is the
presence of a balanced reciprocal translocation resulting in
the PML/RAR-a gene fusion, which represents the target of
ATRA therapy. ATRA is considered to be a safe drug. Pseu-
dotumor cerebri (PTC) is a rare neurological adverse event of
ATRA that was mainly reported in pediatric population. It is
characterized by neurologic and ocular signs and symptoms
of increased intracranial pressure in the absence of any
intracranial pathology or secondary causes of intracranial
hypertension.
Herein we report four cases of young female patients who
were diagnosed with APL and experienced PTC with ATRA
treatment. In three cases ﬂuconazolewas taken concurrently.
Symptoms completely subsided with the temporary with-
drawal of ATRA and discontinuation of ﬂuconazole. PTC
symptoms did not recur after reintroducing ATRA.
In conclusion, we report a case series of young female pa-
tients that is suggestive of young age, female gender and
concurrent use of ﬂuconazole to be associatedwith increased
risk of developing PTC with ATRA treatment. Fluconazole
should not be used concurrently with ATRA. We also con-
clude that the drug could be safely reintroduced once the
symptoms had resolved.239
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Background: T-cell prolymphocytic leukemia (T-PLL) is a
rare neoplasm with an aggressive course and a median
survival of < 1 year. Outcomes have improved since the
advent of alemtuzumab but the duration of response re-
mains short. Hematopoietic stem cell transplantation (HSCT)
is thought to offer long term disease control; however the
feasibility of this approach is not well deﬁned.
Aims: To determine the transplant referral pattern and
outcomes from a large center and to ascertain the survival of
patients (pts) treated with alemtuzumab based regimens.
Methods: Following IRB approval, all pts diagnosed with
T-PLL from 1997-2014 at Mayo Clinic Rochester were iden-
tiﬁed. T-PLL diagnosis was established based on the 2008WHO criteria. Survival was estimated using the Kaplan-
Meier method with log ranks to compare curves.
Results: 41 pts with T-PLL were identiﬁed; 23 (56%) were
males, with a median age at diagnosis of 66 years (range, 32-
85). Median follow up was 18 months (0.4-66.1). At last
follow up, 32 pts (78%) have died. Lymphadenopathy was
present in 68%, hepato-splenomegaly in 61% and cutaneous
inﬁltration in 10%. Median HBwas 13.5 gm/dl (6.6-17.3), WBC
26.25 x 109/L (9.4-551), ALC 17.1 x 109/L (5.7-540) and Plt 164
x 109/L (5-299). Among evaluable pts, FISH analysis was
positive for 14q32 in 27/28, trisomy 8 in 4/10, 11q22 deletion
in 4/6 and 17p deletion in 2/3. Next generation sequencing in
two pts revealed ATM R3008H with JAK3M511I mutations in
one and ATM loss in the other. Twenty (49%) pts received
alemtuzumab based therapy, 13 as intravenous, 4 as subcu-
taneous injection and 3 unknown. Fourteen (34%) received
non-alemtuzumab based therapies, 2 pts received best sup-
portive care, while 4 (10%) have not required treatment to
date. Median survival for pts receiving alemtuzumab based
therapy was 29.5 vs 10.3 months for all other therapies (P
0.0011). Median survival between intravenous vs subcu-
taneous alemtuzumab administration was 40.5 vs 10.9
months (P 0.0011). Thirteen pts were > 70 years of age and
not considered for HSCT. Among the eligible cohort, 22 (85%)
were unable to proceed due to progressive disease (20), lack
of donor (1) or failed autologousmobilization (1). Only 15% of
the eligible pts received HSCT; 3 underwent myeloablative
allogeneic HSCT, while one patient underwent an autologous
HSCT. Median survival post-transplant was 4 months (2.5-
32). All three allogeneic recipients died from graft versus
host disease while the autologous recipient died within 4
months post-transplant from disease progression.
Conclusion: Alemtuzumab based regimens are associated
with improved survival outcome in pts with T-PLL. Although
transplant is thought to be the best consolidation approach, a
striking minority were eligible for such therapy mainly due
to progressive disease. Recurring JAK3 mutations and ATM
deletions reported by us and others should be exploited for
future clinical trials.240
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Background: CD33 is expressed on the surface of myelo-
blasts in w90% of AML, representing a promising, clinically
validated target. SGNeCD33A is an anti-CD33 engineered
cysteine antibody conjugated to w2 molecules of a pyrrolo-
benzodiazepine (PBD) dimer, a highly potent DNA cross-
linking agent. Upon binding, SGNeCD33A is internalized and
transported to the lysosomes where PBD dimer is released
through proteolytic cleavage of the linker, crosslinking DNA
and leading to cell death.
Methods: A phase 1 dose-escalation study (NCT01902329)
evaluating the safety and anti-leukemic activity of SGN-
CD33A is ongoing. AML patients (ECOG 0-1) must have
relapsed disease after initial remission (CR) of > 3 months or
declined induction/consolidation. SGN-CD33A is given IV
q3wk up to 4 cycles and optional maintenance for patients
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who received SGN-CD33A, had anti-leukemic beneﬁt, and
went to allogeneic SCT.
Results: Case 1: A 37-year-old male with AML (inter-
mediate risk cytogenetics) achieved CR with standard in-
duction/consolidation May 2013. He relapsed Dec 2013
and got decitabine before enrolling in SGN33A-001 Jan 2014
(20 mcg/kg). He had ECOG 1, G4 neutropenia, G3 throm-
bocytopenia, and 6-8% blasts. D15 marrow showed a
hypocellularity with no evidence of leukemia. He remained
pancytopenic and his marrow hypoplastic with no evidence
of AML until residual leukemia was identiﬁed at 6.6% by
ﬂow cytometry in hypocellular marrow Mar 2014. He had a
double cord transplant Apr 2014 with ﬂudarabine, cytoxan,
and TBI conditioning regimen. D30 and D100 posttransplant
marrow had no AML and 100% donor chimerism. He is now
5 months posttransplant with no AEs related to SGN-
CD33A.
Case 2: A 41-year-old male with normal karyotype AML
(nucleophosmin cytoplasmic and IDH2 mutations) achieved
CR with high-dose cytarabine + idarubicin induction Jul
2013 which was complicated by acute renal failure requiring
hemodialysis. He had 4 cycles of idarubicin + cytarabine
consolidation. He relapsed Apr 2014 and enrolled in
SGN33A-001 (60 mcg/kg). He had ECOG 0, G3 neutropenia,
and G2 thrombocytopenia. The marrow was 10-20% cellular
with 50% CD33+ blasts. D15 marrow was <5% cellular
without AML. He experienced cellulitis with lymphangitis,
Staphylococcus aureus bacteremia, and persistent fever with
cavitary pulmonary nodules. He had prolonged pancyto-
penia; D64marrowwas< 5% with pockets of hematopoiesis.
He had ﬂudarabine and busulfan conditioning regimen and
MRD allo HSCT complicated by severe mucositis. He had
neutrophil recovery by D16. D30 marrow had no AML and
100% donor chimerism. He is doing well at D75.
Conclusions: These case reports support the anti-leukemic
activity of SGN-CD33A and enablement of allogeneic SCT.
This trial is ongoing to deﬁne MTD and optimize dose and
schedule. Combinations of SGN-CD33A with standard AML
and MDS agents are planned.241
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Introduction: Allogeneic transplantation is the only curative
option for patients with high risk leukemias or MDS. Only
one third of them have an HLA identical sibling donor and
around 60-70% will ﬁnd an unrelated donor; that’s why
haploidentical stem cell transplantation (HAPLO-HSCT) of-
fers a therapeutic option to most of these patients. Myeloa-
blative conditioning (MAC) used to obtain better diseasecontrol than reduced intensity conditioning regimens (RIC),
but with higher toxicity, rendering long term similar results.
Patients and Methods: We retrospectively evaluated the
results in patients diagnosed with high risk leukemias or
MDS of ourMAC-HAPLO regimens (Fludarabine 30mg/m2 x5
days (-6 to -2), Cyclophosphamide14,5 mg/kg x2 days (-6 to
-5), IV Busulfan 3,2 mg/kg x 3 days (BUX3) on days -4 to -2, or
Fludarabine 40 mg/m2 x4 days (-6 to -2) and IV Busulfan 3,2
mg/kg x 4 days (BUX4)) with GVHD prophylaxis based on
PT-CY (50 mg/kg on days +3 and +4) and a calcineurin in-
hibitor plus mycophenolate from day +5, performed in GETH
centers.
Results: From Feb 2011, 24 MAC-HAPLO have been done in 7
centers. Median age was 37 years (15-65), 58% were males
and all were in advanced disease phase or presented high
risk features (AML 16/ALL 4/MDS 2/ CML-BC 1/ CMML 1).
Previous HSCT had been employed in 21% (autologous in 1,
allogeneic in 4), and in 79% the HAPLO-HSCT was their ﬁrst
transplant. Disease status at HAPLO-HSCT was morphologic
CR in 83%, but with persistent disease (morphologic or
MRD+ by ﬂow or molecular markers) in 67%. BM was the
graft source in 3 patients (12.5%) and PBSC in 21 (87.5%), non
T-cell depleted in all cases. The haploidentical donor was the
patient’s mother (21%), father (12.5%), siblings (41.5%) or
offspring (25%). MAC regimenwas BUX3 in 8 (33%) and BUX4
in 16 patients (67%). Median infused CD34+ cells were
4,93x10e6/kg (3,20-8,43). Median neutrophils engraftment
was reached at day +16 (13-29) and platelets >20K at day
+27 (11-131). Complete chimerismwas obtained at a median
of 22 days (13-44) in 21 evaluated patients. Cumulative
incidence (CI) of non-relapse mortality (NRM) was 21.5% at 1
year. CI of grade II-IV acute GVHDwas 45.5% at day +100, and
grade III-IV was 9%. CI of chronic GVHD at 1 year was 35%,
being extensive in 8% . No differences in acute or chronic
GvHD CI were seen when comparing BUX3 against BUX4.
After a median follow-up of 15 months (3-31), estimated
18-months event-free survival (EFS) and overall survival
(OS) were 63% and 75% respectively. CI of relapse or pro-
gression was 19.5%. No signiﬁcant differences in NRM, EFS,
OS and relapse incidence were detected between BUX3 and
BUX4. The effect of CR prior to MAC-HAPLO has not been
appropriately assessed due to the limited number of events
in our series.
Conclusions: IV Busulfan based MAC-HAPLO with PT-CY in
the treatment of high risk leukemias and MDS offers good
disease control with manageable toxicity, with either BUX3
or BUX4.242
Allogeneic Hematopoietic Stem Cell Transplantation
(alloHSCT) Following Blinatumomab-Induced Remission
in Pediatric Patients with Relapsed/Refractory (r/r)
B-Precursor Acute Lymphoblastic Leukemia (ALL):
Preliminary Results from a Phase I/II Stud
Rupert Handgretinger 1, Lia Gore 2, Gerhard Zugmaier 3,
Franco Locatelli 4, Christian M. Zwaan 5, Deepa Bhojwani 6,
Peter Bader 7, Maureen M. O’Brien 8, Tanya M. Trippett 9,
Benoît Brethon 10, Carmelo Rizzari 11, Paul Gerhardt Schlegel 12,
Gérard Michel 13, Phillip Barnette 14, Chiara Messina 15,
Kuolung Hu 16, Noemi Mergen 3, Anja Fischer 3,
James Whitlock 17, Arend von Stackelberg 18. 1 University of
Tübingen, Tübingen, Germany; 2 Children’s Hospital Colorado,
Aurora, CO; 3 Amgen Research (Munich) GmbH, Munich,
Germany; 4 Ospedale Pediatrico Bambino Gesu, University of
Pavia, Rome, Italy; 5 Erasmus Medical Center, Sophia Children’s
